Sign in

    Jane Lindenman

    Research Analyst at Private Investor

    Jane Lindenman is an Analyst at Private Investor, specializing in equity research and portfolio analysis across various sectors. She covers several growth-focused companies, providing actionable investment insights and has built a reputation for thorough fundamental analysis, though no verified third-party performance metrics or rankings have been found to date. Lindenman launched her career in financial analysis before joining Private Investor, but specific previous firms and the year of her current appointment are not publicly documented. While her profile indicates expertise in securities and investment analysis, there is no publicly confirmed record of professional credentials such as FINRA registration or securities licenses.

    Jane Lindenman's questions to IMMUCELL CORP /DE/ (ICCC) leadership

    Jane Lindenman's questions to IMMUCELL CORP /DE/ (ICCC) leadership • Q1 2025

    Question

    Asked about the distinction between investigational use and full approval for Re-Tain, the company's plans for selling shares given its recent profitability, and whether it will provide future financial projections.

    Answer

    Investigational use is a non-revenue-generating step to gather market data while awaiting final FDA approval. The company will continue to opportunistically use its ATM share offering to fund long-term capital needs but has been less active recently. They are hesitant to provide detailed future projections, especially for the novel Re-Tain product, and will stick to early top-line revenue announcements.

    Ask Fintool Equity Research AI